TScan Therapeutics (TCRX) has provided an update.
TScan Therapeutics, Inc. has provided promising updates on its clinical programs targeting solid tumors and hematological malignancies, highlighting the expansion of its ImmunoBank and the promising results from its TCR-T cell therapy candidates, TSC-100 and TSC-101. Early May 2024 will see the first patients dosed in a Phase 1 solid tumor study, with initial data expected later in the year. In the heme malignancies program, treated patients remain relapse-free with no detectable cancer, and further trials are scheduled for later in the year to assess safety and efficacy, with hopes to initiate a registration trial in 2025.
See more insights into TCRX stock on TipRanks’ Stock Analysis page.
